

PRODUCT MONOGRAPH

ACID CONTROL

Famotidine Tablets USP

20 mg

Histamine H₂-Receptor Antagonist

**APOTEX INC.
150 Signet Drive
Toronto, Ontario
M9L 1T9**

**DATE OF REVISION:
September 17, 2019**

Control Number: 230567

Table of Contents

PART I: HEALTH PROFESSIONAL INFORMATION	3
SUMMARY PRODUCT INFORMATION	3
INDICATIONS AND CLINICAL USE	3
CONTRAINDICATIONS	3
WARNINGS AND PRECAUTIONS	3
ADVERSE REACTIONS.....	5
DRUG INTERACTIONS	8
DOSAGE AND ADMINISTRATION	8
OVERDOSAGE	9
ACTION AND CLINICAL PHARMACOLOGY.....	10
STORAGE AND STABILITY	12
DOSAGE FORMS, COMPOSITION AND PACKAGING	12
PART II: SCIENTIFIC INFORMATION	13
PHARMACEUTICAL INFORMATION.....	13
CLINICAL TRIALS	14
DETAILED PHARMACOLOGY	15
TOXICOLOGY	16
REFERENCES	18
PART III: CONSUMER INFORMATION	19

ACID CONTROL
Famotidine Tablets USP

PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

Route of Administration	Dosage Form / Strength	All Nonmedicinal Ingredients
oral	Film-coated tablet/20 mg	carnauba wax, colloidal silicon dioxide, croscarmellose sodium, ferric oxide red and ferric oxide yellow, hydroxypropyl methylcellulose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, stearic acid and titanium dioxide

INDICATIONS AND CLINICAL USE

ACID CONTROL (famotidine tablets 20 mg) is indicated for:

- the treatment of conditions where a controlled reduction of gastric secretion is required, such as acid indigestion, heartburn, sour or upset stomach;
- the prevention of acid indigestion, heartburn, sour or upset stomach when associated with the consumption of food and/or beverage including nocturnal symptoms associated with the evening meal and expected to cause sleep disturbance.

CONTRAINDICATIONS

- Patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container.

Cross sensitivity in this class of compounds has been observed. Therefore, ACID CONTROL should not be administered to patients with a history of hypersensitivity to other H₂ receptor antagonists (H₂RAs).

WARNINGS AND PRECAUTIONS

General

In clinical trials, patients with other underlying acid gastrointestinal diseases (e.g. duodenal ulcer, gastric ulcer) did not experience complications; in general, they did not exhibit a clinically significant deterioration in their condition. However, if patients have difficulty swallowing, pain on swallowing, unexpected weight loss, severe vomiting, melaena (black stools), choking, chest pain, or if abdominal discomfort persists, patients should consult a physician to determine the

underlying cause. Symptomatic response to therapy with ACID CONTROL does not preclude the presence of gastric malignancy.

Patients with severe coexisting illness should consult a physician before commencing therapy with ACID CONTROL.

Patients consuming nonsteroidal anti-inflammatory drugs may have dyspepsia as a side effect of these medicines and should consult a physician or a pharmacist before taking ACID CONTROL.

Patients over 40 who are experiencing heartburn for the first time and patients who have noticed unintentional weight loss should consult a physician before using the product.

Further medical evaluation is required if therapy exceeds two weeks of continuous treatment, if two 14 day courses of treatment are needed at intervals of less than 6 weeks, or if heartburn is frequent (>3 times per week) and/or severe.

Gastrointestinal

Patients with a previous history of ulcer disease complications, those who are experiencing unintended weight loss in association with dyspeptic symptoms, and those who are middle-aged or older with new or recently changed dyspeptic symptoms should consult a physician before commencing therapy with ACID CONTROL.

Renal

Patients with severe kidney disease should consult a physician before commencing therapy with ACID CONTROL. A dosage adjustment may be necessary in patients with moderate or severe renal impairment (creatinine clearance less than 60 mL/min/1.48 m²).

Since CNS adverse effects have been reported in patients with moderate and severe renal insufficiency, longer intervals between doses or lower doses may need to be used in patients with moderate (creatinine clearance 30 to 50 mL/min) or severe (creatinine clearance < 30 mL/min) renal insufficiency to adjust for the longer elimination half-life of famotidine (see ACTION AND CLINICAL PHARMACOLOGY, Pharmacokinetics and DOSAGE AND ADMINISTRATION, Dosage Adjustment for Patients with Moderate or Severe Renal Insufficiency)

Special Populations

Pregnant Women: Reproductive studies have been performed in rats and rabbits at oral doses of up to 2000 and 500 mg/kg/day, respectively (approximately 2500 and 625 times the maximum recommended prescription human dose [80 mg], respectively), and have revealed no evidence of impaired fertility or harm to the fetus due to famotidine. There are, however, no adequate or well-controlled studies in pregnant women.

Since the safe use of famotidine tablets in pregnant women has not been established, pregnant women should not use famotidine tablets unless directed otherwise by a physician.

Nursing Women: Famotidine is detectable in human milk. Nursing mothers should either stop this drug or should stop nursing.

Pediatrics (<12 years of age): Safety and effectiveness in children have not been established. Famotidine tablets should not be administered to children under 12 years of age.

Geriatrics: No dosage adjustment is required based on age (see ACTION AND CLINICAL PHARMACOLOGY, Pharmacokinetics). This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see PRECAUTIONS, Renal and DOSAGE AND ADMINISTRATION, Dosage Adjustment for Patients with Moderate or Severe Renal Insufficiency).

ADVERSE REACTIONS

Adverse Drug Reaction Overview

Famotidine 20 mg tablets have been demonstrated to be generally well tolerated.

Clinical Trial Adverse Drug Reactions

The following adverse reactions have been reported in $\geq 1\%$ of patients using famotidine 20 mg tablets in controlled clinical trials (prevention or treatment): headache (6.9%), diarrhea (2.9%), upper respiratory infection (2.9%), vomiting (2.4%), constipation (2.0%), nausea (2.0%), pharyngitis (2.0%), flu-like illness (1.6%), back pain (1.2%) and rash (1.2%). These occurred with comparable frequency across treatment groups and control groups.

Less Common Clinical Trial Adverse Drug Reactions (<1%)

Other reactions reported in patients using famotidine 20 mg tablets in controlled clinical trials at rates <1%. These observations are listed.

Body as a Whole/Site Unspecified 1.0%

Asthenia/Fatigue 0.1%

Pain-abdominal 0.3%

Pain-chest 0.1%

Each of the following at <0.1%: fever, infection-viral, pain-pelvic

Cardiovascular System 0.2%

Each of the following at <0.1%: extravasation, premature atrial contraction, premature ventricular contraction

Digestive System 1.7%

Dyspepsia 0.1%

Each of the following at <0.1%: erosive esophagitis, esophagitis, gingivitis and glossodynia

Musculoskeletal System 0.5%

Myalgia 0.1%

Pain - shoulder 0.1%

Each of the following at <0.1%: pain-foot, pain-knee, pain-neck

Nervous System and Psychiatric 2.4%

Anxiety 0.1%
Dizziness 0.1%
Each of the following at <0.1%: agitation, migraine

Respiratory System 1.3%

Sinusitis 0.1%
Each of the following at <0.1%: bronchitis, congestion-nasal, cough, dry throat, influenza, sinus disorder, sneezing, wheezing

Skin and Skin Appendages 0.4%

Each of the following at <0.1%: edema – angioneurotic, infection-skin, laceration, measles

Special Senses 0.2%

Each of the following at <0.1%: eustachian tube disorder, hemorrhage – corneal, pain-ear

Urogenital System 0.4%

Mass, breast 0.1%
Each of the following at <0.1%: benign prostatic hypertrophy, dysuria, hematuria, impotence, menstruation disorder, urinary frequency

Abnormal Hematologic and Clinical Chemistry Findings

Laboratory parameters may be affected during treatment with famotidine, but the changes are usually not considered serious. Among the laboratory changes that were reported during clinical trials were increases in AST, ALT, BUN, and WBC count and serum creatinine, and decreases in hemoglobin and hematocrit. These changes were rarely of clinical significance. No famotidine-treated patients/subjects had to be discontinued from therapy because of laboratory adverse experiences.

Post-Market Adverse Drug Reactions

During marketed use of prescription doses of famotidine, the following adverse reactions have been reported: urticaria, liver enzymes abnormalities, cholestatic jaundice, asthenia, fatigue, abdominal discomfort and pain, abdominal pain upper, diarrhea, dry mouth, nausea, vomiting, rash, hypersensitivity, anaphylaxis, angioedema, malaise, and somnolence. Toxic epidermal necrolysis has been reported very rarely with H₂ receptor antagonists. As with other H₂-receptor antagonists, cases of bradycardia, A-V block and other arrhythmia have been reported rarely in patients treated with famotidine.

The following adverse reactions have been reported, however, a causal relationship to therapy with famotidine has not been established: agitation, confusion, hallucinations, depression, disorientation, mental disorder, insomnia, psychotic disorder, pruritus, alopecia, photosensitivity, Steven Johnson syndrome, hypotrichosis, neutropenia, anaemia, paraesthesia, dysgeusia, convulsions, syncope, grand mal seizures, rare cases of impotence, thrombocytopenia, pancytopenia, leukopenia, bone marrow depression and agranulocytosis.

Gynecomastia has been reported rarely. In most cases that were followed up, it was reversible after discontinuing treatment.

Post-Market Data

Adverse drug reactions (ADRs) identified during Post-marketing experience with famotidine are included in Table 1 below. The frequencies are provided according to the following convention based on spontaneous reporting rates:

Very common	≥1/10
Common	≥1/100 and <1/10
Rare	≥1/10,000 and < 1/1,000
Very rare	<1/10,000
Not known (cannot be estimated from the available data)	

Table 1: Adverse Drug Reactions Identified during Post-Marketing Experience with Famotidine for OTC use by Frequency Category Estimated from Clinical Trials

SOC	Adverse Event Preferred Term	Clinical Trials	Frequency Category Spontaneous Reporting Rates
Nervous System Disorders			
	Dizziness		
	Asthenia, Fatigue	Uncommon*	Very rare
	Somnolence	Uncommon*	Very rare
		Rare*	Very rare
Gastrointestinal Disorders			
	Abdominal discomfort and pain	Uncommon*	Very rare
	Abdominal pain upper	Not known	Very rare
	Diarrhea	Uncommon*	Very rare
	Dry mouth	Rare*	Very rare
	Nausea	Uncommon*	Very rare
	Vomiting	Uncommon	Very rare
Skin and Subcutaneous Tissue Disorders			
	Pruritus	Rare*	Very rare
	Rash	Uncommon*	Very rare
	Urticaria	Not known	Very rare
Immune System Disorders			
	Hypersensitivity	Not known	Very rare
	Anaphylactic reaction	Not known	Very rare
	Angioedema	Not known	Very rare
General Disorders and Administrative Site Conditions			
	Malaise	Not known	Very rare

*not significantly greater than Placebo (p<0.05)

In the above table, ADRs in the first frequency category column are presented based on incidence in adequately designed clinical trials or epidemiology studies, if available, or when incidence is unavailable, frequency category is listed as ‘Not known’. In the second frequency category column the same ADRs are presented frequency categories estimated from spontaneous reporting rates where the numerator represents total number reported Company Adverse Events under given Preferred Terms or medical concept and denominator represents exposure data calculated from sales data.

DRUG INTERACTIONS

Overview

Studies with famotidine in man, in animal models, and in vitro have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system. Compounds tested in man have included warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine. Indocyanine green as an index of hepatic blood flow and/or hepatic drug extraction has been tested and no significant effects have been found.

Concomitant use of aluminum hydroxide/magnesium hydroxide at commonly used doses, does not influence the pharmacodynamics or bioavailability of ACID CONTROL. Famotidine does not affect gastric alcohol dehydrogenase and, consequently, blood ethanol levels.

Patients should consult a physician before using this product together with any of the following drugs:

Itraconazole.

Concomitant use of famotidine with the antifungal agent itraconazole results in significantly reduced peak and trough plasma concentrations of itraconazole, which may result in reduced antifungal efficacy.

Calcium carbonate

The hypophosphatemic effect of calcium carbonate is attenuated with concomitant use of H₂-antagonists in patients undergoing chronic hemodialysis.

Drug-Food Interactions

Not known

Drug-Herb Interactions

Not known

Drug-Laboratory Interactions

Not known

DOSAGE AND ADMINISTRATION

Dosing Considerations

Antacids may be given concomitantly if needed. It is not appropriate to use this product and other H₂ Receptor Antagonists concomitantly.

Recommended Dose and Dosage Adjustment

Adults and children 12 years of age or older:

For relief of heartburn, acid indigestion and sour or upset stomach: The patient should take one tablet; to be swallowed whole with a glass of water. To prevent these symptoms, one tablet should be taken 10 to 15 minutes before eating food or drinking beverages that cause heartburn.

Dosage Adjustment for Patients with Moderate or Severe Renal Insufficiency

Patients with severe kidney disease should consult a physician before commencing therapy with famotidine. A dosage adjustment may be necessary in patients with moderate or severe renal impairment (creatinine clearance less than 60 mL/min/1.48m²). In patients with moderate (creatinine clearance 30 to 50 mL/min), the elimination half-life of famotidine is increased. For patients with severe renal insufficiency, it may exceed 20 hours, reaching approximately 24 hours in anuric patients. Since CNS adverse reactions have been reported in patients with moderate and severe renal insufficiency, to avoid excess accumulation of the drug in patients with moderate or severe renal insufficiency, the dose of famotidine may be reduced to half the dose or the dosing interval may be prolonged to 36 to 48 hours as indicated by the patient's clinical response.

Administration

The patient should not take more than 1 tablet at a time and the patient should not take more than two tablets in 24 hours. Therapy should not exceed two weeks of continuous treatment without medical consultation.

OVERDOSAGE

Doses of up to 800 mg/day have been employed in patients with pathological hypersecretory conditions with no serious adverse effects. In the event of overdose, treatment should be symptomatic and supportive. Unabsorbed material should be removed from the gastrointestinal tract, the patient should be monitored, and supportive therapy should be employed.

The oral LD₅₀ of famotidine in male and female rats and mice was >5000 mg/kg.

Intentional exposure is defined as a purposeful action in patients who use a substance inappropriately for self-destructive or manipulative reasons, including suicides, suicide gestures, and attempts. The inappropriate use of famotidine (single agent) or with other agents for suicide attempts is very uncommon. There have been no reports that identified an overdose fatality with famotidine (single agent) or taken with other agents. For all overdose exposures, the duration of clinical effects, considered moderate or major, resolved in ≤3 days, the large majority and single-agent famotidine exposures resolved in ≤ 24 hours.

According to data from the Toxic Exposure Surveillance System (TESS) of the American Association of Poison Control Centers (AAPCC), of the single-agent famotidine exposures, the most common cardiovascular symptom was tachycardia (0.3%). For neurological symptoms, the proportions of subjects who experienced drowsiness/lethargy was 1.5%; headache, 0.6%; dizziness/vertigo, 1.0%; and agitated/irritable, 0.5%. Abdominal pain (1.9%), nausea (1.2%), vomiting (1.6%), and diarrhea (1.0%) were observed as gastrointestinal side effects. It is not known the extent to which the use of an emetic in hospital emergency rooms may have contributed to the occurrence of the symptoms nausea and vomiting.

For management of a suspected drug overdose, contact your regional Poison Control Centre immediately.

ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action

Famotidine is a competitive inhibitor of histamine H₂-receptors. The primary clinically important pharmacologic activity of famotidine is inhibition of gastric juice secretion. Famotidine reduces the acid and pepsin content, as well as the volume, of basal, nocturnal, and stimulated gastric secretion.

Pharmacodynamics

In both normal volunteers and hypersecretors, famotidine inhibited basal nocturnal and daytime gastric secretion. The duration of effect is up to 12 hours. In addition famotidine inhibits acid secretion stimulated by a variety of stimuli, such as pentagastrin and food.

Pharmacokinetics

Famotidine exhibits a linear pharmacokinetic profile for AUC and gastric pH in the 5 to 40 mg range. In this same range, associations have been demonstrated between mean plasma famotidine concentrations and mean inhibition of meal-stimulated acid secretion. However “area under the gastric pH-time curve” has not been shown to be directly associated or correlated with heartburn relief.

Clinical studies have demonstrated that: famotidine 20 mg prevents heartburn in patients with moderate to severe symptoms when taken before a meal. A dose response is demonstrated between 10 mg famotidine and 20 mg famotidine in successfully preventing acid-related symptoms and effectively relieving heartburn.

Famotidine is incompletely absorbed. The bioavailability of oral doses is 40 to 45%. Bioavailability may be slightly increased by food; however, this effect is of no clinical significance. Bioavailability of ACID CONTROL at recommended doses is not affected by customary doses of antacids. Famotidine undergoes minimal first-pass metabolism. After oral doses, peak plasma levels occur in 1 to 3 hours.

Plasma levels after multiple doses are similar to those after single doses in studies where patients received 20mg famotidine b.i.d. (8 a.m. and 5 p.m.) Intravenously for a total of 15 doses, the last dose being administered in the morning of Day 8. Fifteen to 20% of famotidine in plasma is protein bound. Famotidine has an elimination half-life of 2.5 to 3.5 hours. Famotidine is eliminated by renal (65 to 70%) and metabolic (30 to 35%) routes. Renal clearance is 250 to 450 mL/min., indicating some tubular excretion.

Twenty-five to 30% of an oral dose and 65 to 70% of an intravenous dose are recovered in the urine as unchanged compound. The only metabolite identified in man is the S-oxide. There is a close relationship between creatinine clearance values and the elimination half-life of famotidine. In patients with severe renal insufficiency, i.e., creatinine clearance less than 30mL/min., elimination half-life of famotidine may exceed 20 hours (see DOSAGE AND ADMINISTRATION). In elderly patients, there are no clinically significant age-related changes in the pharmacokinetics of famotidine. However, in elderly patients with decreased renal function,

the clearance of the drug may be decreased (see PRECAUTIONS, Special Populations, Geriatrics).

Absorption: The absorption of famotidine was studied in two animal species. Absorption was 28% in the rat and 43% in the dog.

Distribution: The distribution of famotidine was studied in two animal species. The plasma half-life in dogs was 2.5 hours, which was unchanged after repeated doses, indicating no tendency for the drug to accumulate. In rats, the highest levels of radioactivity after an oral dose of famotidine were found in the gastrointestinal tract, kidneys, liver, submandibular glands, arteries, epiphyseal membrane, fascia, and uvea. The distribution pattern was not affected on repeated dosing. Famotidine did not effectively cross the blood-brain or placental barrier of rats. It was present in rat milk.

Metabolism: The only metabolite of famotidine in rat and dog urine was the sulfoxide derivative, which was present in minor amounts.

Excretion: Urinary and fecal excretion of radioactivity in rats accounted for 28% and 70%, respectively, of an oral dose, compared to 83% and 17% respectively, of an intravenous dose. About 2.4% of the dose in rats was excreted in the bile. Dogs excreted 45% of an oral dose in the urine, compared to 100% of an intravenous dose.

Effects on Liver Microsomal Drug-Metabolizing Enzymes

Famotidine did not affect pentobarbital or hexobarbital sleeping times and it did not affect ascorbic acid excretion, suggesting that famotidine does not induce drug-metabolizing enzymes. Famotidine caused none of the changes induced by cimetidine on the pharmacokinetics of diazepam, warfarin, and propranolol. Famotidine produced only minimal suppression of aminopyrine and diazepam N-demethylase activity in vitro, and showed little affinity for testosterone hydroxylases of mouse liver in vitro.

Gastrointestinal Effects other than Antisecretory

Famotidine prevented gastric erosions induced in rats by cold restraint, water immersion, pyloric ligation, or drugs such as acetylsalicylic acid, histamine or prednisolone; also duodenal ulcers caused by cysteamine and mepirizole. It also significantly accelerated the healing of the gastric lesions induced by acetic acid and the duodenal ulcers produced by mepirizole.

The antiulcer effect of famotidine plus magnesium and aluminum hydroxides was greater than the sum of the effects of these drugs used separately.

Famotidine inhibited the gastric lesions and hemorrhage resulting from blood removal and histamine injection in anesthetized rats.

In normal rats, famotidine had no effect on the concentration of gastric mucosal histamine, but it did reduce the levels of cAMP, particularly in response to histamine stimulation.

In anaesthetized cats, famotidine had no effect on the intragastric electropotential when tested at intragastric doses more than ten-fold greater than those required to block gastric secretion maximally.

Cardiorenal Effects

The cardiorenal effects of famotidine were studied in dogs and rats. Ten mg/kg of famotidine administered orally were without effect on the blood pressure of spontaneously hypertensive rats. In anaesthetized dogs, intravenous administration of 1.0 and 4.0 mg/kg of famotidine was without effect on cardiovascular parameters relating to the autonomic nervous system, blood pressure, heart rate, or respiratory function. In conscious dogs, an oral dose of 10 mg/kg was without diuretic effect.

Central Nervous System Effects

The effects of famotidine on the central nervous system were studied in squirrel monkeys, mice, and cats. In monkeys famotidine had a bidirectional effect on lever pressing (avoidance response) causing an increase at the low dose (1.0 mg/kg p.o.) and a small decrease at 9 mg/kg. In mice following intraperitoneal administration of 6 to 150 mg/kg no overt behavioral signs or symptoms of central nervous system activity were observed. In mice famotidine was not active as an antagonist of the CNS actions of TRH, neurotensin, substance P, or amphetamine. Famotidine was free of major or minor tranquilizing, anticonvulsant, anticholinergic, ganglionic blocking, or dopaminergic activity. In cats, famotidine did not affect the EEG or arousal response but did prolong the duration of hippocampal after-discharge. Only 4% of the plasma concentration of the drug was detected in the cerebrospinal fluid.

STORAGE AND STABILITY

Store at room temperature (15°C to 30°C). Protect from light and moisture.

DOSAGE FORMS, COMPOSITION AND PACKAGING

ACID CONTROL, 20 mg: beige coloured, D-shaped, film-coated tablets engraved APO over 20 on one side. Available in bottles of 100 tablets and blister packs of 6, 8, 10, 18, 24 and 30 tablets.

Composition

Each film-coated tablet for oral administration contains 20 mg of famotidine and the following non-medicinal ingredients: carnauba wax, colloidal silicon dioxide, croscarmellose sodium, ferric oxide red and ferric oxide yellow, hydroxypropyl methylcellulose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, stearic acid and titanium dioxide.

PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance


Proper Name: famotidine

Chemical Name: N³-(aminosulfonyl)-3-[[[2-[(diaminomethylene)amino]-4-thiazolyl]methyl]thio] Propanimidamide.

Molecular Formula: C₈H₁₅N₇O₂S₃

Molecular weight: 337.44 g/mol

Structural Formula:



Description: Famotidine is a white to pale yellow crystalline compound that is freely soluble in glacial acetic acid, slightly soluble in methanol, very slightly soluble in water and practically insoluble in ethanol.

CLINICAL TRIALS

Study demographics and trial design

Two treatment studies were conducted. In these studies, P017 and P019 involving 552 patients and 500 patients respectively, 20 mg famotidine, 10 mg famotidine or placebo was taken to treat episodic heartburn. For P017 the probability of achieving complete relief of a heartburn episode within 1 hour of dosing was 0.379 for famotidine 20 mg, 0.344 for famotidine 10 mg and 0.235 for placebo. For P019 the probability of achieving complete relief within 1 hour of dosing was 0.362 for 20mg famotidine, 0.325 for 10mg famotidine and 0.217 for placebo. For both of these studies the patients in the famotidine 20mg group had a numerically greater probability of complete relief within 1 hour than patients in the famotidine 10mg group.

Three prevention studies were conducted. In one study (P117) involving 1227 patients, 20 mg or 10 mg of famotidine or placebo was taken 10 minutes before a provocative meal of chili, cola and chocolate. The percentage of subjects, who reported no heartburn in the 3 hour interval after eating, was 37.9% (185 of 488 patients) for 20 mg famotidine, 30.0% (147 of 490 patients) for 10 mg famotidine and 18.9% (47 of 249 patients) for placebo.

In a second study (P128) involving 1332 patients, conducted under the same conditions, the percentage of subjects who reported no heartburn in the 3 hour interval after eating, was 41.2% (219 of 531 patients) for 20 mg famotidine, 35.4% (190 of 537 patients) for 10 mg famotidine and 26.9% (71 of 264 patients) for placebo. The difference between the response to the 20 mg dose and the 10 mg dose in both of these trials was statistically significant.

In a third study (P114) of similar, but not identical design, involving 794 subjects who suffer severe heartburn, the percentage of subjects who reported no heartburn in the 3 hour interval after eating, was 10.7% (28 of 261 patients) for 20 mg famotidine, 7.7% (21 of 271 patients) for 10 mg famotidine and 4.2% (11 of 262 patients) for placebo. In this trial there was no significant difference between the response to 20 mg and 10 mg famotidine. The response to 20 mg famotidine was significantly different from placebo, whereas the response to 10 mg famotidine was not.

Study results

When the results of these clinical trials were analyzed in terms of peak heartburn severity in the period 3 hours after the meal (based on the percentages of patients reporting none, mild, moderate or severe heartburn), in study P117, the peak heartburn severity for 20 mg famotidine was significantly less than that for 10 mg famotidine and for placebo. The mean heartburn severity for 10 mg famotidine was also significantly less than placebo. In study P128, the mean heartburn severity for both 20 and 10 mg famotidine were both significantly less than placebo, but were not significantly different from one another. In P114 there was a significant difference among treatments for the 20 mg famotidine group versus placebo. The peak heartburn severity of those patients who took 10 mg famotidine was not significantly different from either the placebo group or from the group that took 20 mg famotidine.

DETAILED PHARMACOLOGY

I. ANIMAL PHARMACOLOGY

Famotidine inhibits gastric secretion evoked by histamine and other secretagogues. In dogs, the ED₅₀ was 0.03 mg/kg after oral or intravenous administration of famotidine. An oral dose of 2.1 mg/kg in dogs inhibited gastric secretion for at least 24 hours. An oral dose of 3 mg/kg one hour prior to feeding inhibited the acid response in dogs during a 4-hour post-feeding period by an average of 96%.

Mechanism of Action

Famotidine is a specific, competitive, H₂ receptor antagonist. There was no effect *in vitro* on responses mediated by H₁-histamine, beta₁-adrenergic, or cholinergic receptors. Famotidine was inactive in radioligand binding to dopaminergic, neuroleptic, serotonergic, adrenergic, cholinergic, and purinergic sites. Famotidine was also inactive in an androgen receptor assay.

The interaction between famotidine and H₂-receptors is tissue-dependent. In guinea pig lungs and rabbit gastric glands the effects of famotidine were surmountable and readily reversible on washout, indicating classic competitive inhibition at the H₂ receptor sites. However, in guinea pig atria, famotidine acted as a non-competitive H₂ antagonist, and recovery after washout of famotidine was retarded.

II. HUMAN PHARMACOLOGY

After oral administration, a dose-response relationship was clearly demonstrated from 10 mg and 20 mg famotidine in terms of raising gastric pH between and after meals. Famotidine doses of 10 mg and 20 mg were demonstrated to produce a statistically significant effect on gastric pH as compared to placebo. The maximum effect as measured by AUC (intra-gastric pH/hour) was seen with famotidine 20 mg. The mean AUC for 20mg famotidine, 10mg famotidine and placebo were 2.64, 2.13 and 1.35 respectively. The maximum effect as measured by percentage of intra-gastric pH values >3 (12 hour interval) was seen with famotidine 20mg. The values for 20mg famotidine, 10mg famotidine and placebo were 32.65%, 21.37% and 5.83% respectively. Famotidine was well-tolerated at all dose levels.

Fasting and postprandial serum gastrin levels may be slightly elevated during periods of drug antisecretory effect, and with chronic therapy an increase in gastric bacterial flora may occur. It has been postulated that H₂RAs and proton pump inhibitors (PPIs) could increase susceptibility to pulmonary infections by increasing gastric pH. However the safety surveillance database does not support this issue would be a concern when famotidine 20mg is used acutely as directed in the management of heartburn. Gastric emptying and exocrine pancreatic function are not affected by famotidine.

Other Effects

Systemic pharmacologic effects of famotidine involving the CNS, cardiovascular, respiratory or endocrine systems have not been found to date. Serum prolactin levels do not rise after intravenous bolus doses of 20 mg of famotidine and no antiandrogenic effects have been detected.

TOXICOLOGY

Acute Toxicity

Species	Sex	Route	LD ₅₀ (mg/kg)
Mouse	M	P.O.*	4,684
	F	P.O.*	3,233
Mouse	M	I.V. (4%)	254
	F	I.V. (4%)	358
Rat	M	P.O.*	4,907
	F	P.O.*	4,049
Rat	M	I.P.	987
	F	I.P.	814

*In solution (acidic, 50°C to 55°C deionized water).

Subacute and Chronic Toxicity

Famotidine is well tolerated by both rats and dogs at doses of 2 g/kg twice a day orally in subacute studies and at doses up to 1000 or 2000 mg/kg/day for one year in these species. Eosinophilic cytoplasmic granularity of gastric chief cells was seen at a higher incidence in rats given 200 mg/kg/day or more of the compound compared to controls. This is considered as a secondary effect due to the exaggerated pharmacologic activity of the compound at these extremely high dosage levels and is considered of no toxicologic significance. In a 106-week study in rats designed to study the carcinogenic potential of the compound, this gastric change did not progress to hyperplasia or neoplasia. Similarly, mice (given the compound for 92 weeks) showed no evidence of a neoplastic potential. Based on the results from studies performed using pharmacologically-related compounds, this change was fully reversible.

Intravenous administration of famotidine was well tolerated by rats for 13 weeks at dosage levels of up to 20 mg/kg/day and by dogs, except for occasional emesis, at dosage levels of up to 10 mg/kg/day for 5 to 26 weeks.

Reproduction Studies

In studies with rats given oral doses of up to 2000 mg/kg/day or intravenous doses of up to 200 mg/kg/day (approximately 2500 and 250 times the maximum recommended prescription human dose, respectively), fertility and reproductive performance were not affected.

Famotidine given orally to pregnant rats up to 2000 mg/kg/day or intravenously at dosage levels up to 200 mg/kg/day, from Days 7 to 17 of pregnancy did not reveal any evidence of embryoletality or teratogenicity.

Oral administration of famotidine to pregnant rabbits from Days 6 to 18 of pregnancy at dosage levels up to 500 mg/kg/day revealed no evidence of embryoletality or teratogenicity.

Mutagenicity

Famotidine was tested in a reverse-mutation test (Ames test) using *Salmonella typhimurium* and

Escherichia coli with and without metabolic activation. No mutagenic potential was seen. These same studies were performed with famotidine/sodium nitrite reaction mixture and C-nitroso derivatives of famotidine and they were also negative. Famotidine and C-nitroso derivatives of famotidine were tested in the rec-assay using *Bacillus subtilis* H17 and M45 and the tests were negative for DNA-damaging capacity of the compounds. In *in vivo* studies in mice, a micronucleus test and a chromosomal aberration test, no evidence of a mutagenic effect was seen.

Carcinogenicity

A 92-week oral carcinogenicity study was conducted in mice at doses of 20, 200 and 2000 mg/kg/day. No evidence of a carcinogenic potential was seen. A 106-week oral carcinogenicity study in rats given doses of 20, 200 and 2000 mg/kg/day did not reveal any carcinogenic potential for famotidine.

Special Studies

The effects of famotidine on the thyroid of rats were evaluated after five weeks of oral administration at doses up to 2000 mg/kg/day. No evidence of treatment-related alterations of serum thyroid hormone levels, thyroid weight or the microscopic appearance were seen after administration of famotidine.

In immunogenicity studies, no effect on the production of IgE antibodies was seen in the sera of mice which were injected, once intraperitoneally, with famotidine alone (up to 2 mg/8 mL/kg) or coupled with either mouse serum albumin or ovalbumin. The sera were used to measure passive cutaneous anaphylaxis in rats which were then challenged with solutions of antigens similar to those antigens used for the initial dose in mice. Similarly, no evidence of an anaphylactic reaction was seen in guinea pigs challenged intravenously with famotidine after initiating doses (three times, subcutaneously, at six-day intervals) of up to 10 mg/mL.

REFERENCES

1. Hayakawa A, Che K, Miyoshi A, Harasawa S, Miwa T, Makabatake T. Properties of famotidine in relation to safety. *Ital J Gastroenterol* 1984; 16: 174 - 176.
2. McCallum RW, Kuljian B, Chremos AN, Tupy-Visich MA, Huber PB. Prolonged gastric antisecretory effect of a novel H₂-receptor inhibitor, MK-208. *Gastroenterology (in Soc. Proc.)* 1983; 84: 1245.
3. Barzaghi N, Gratti G, Crema F, Perucca E. Impaired bioavailability of famotidine given concurrently with a potent antacid. *J Clin Pharmacol* 1989; 29: 670 - 72.
4. Echizen H, Ishizaki T. Clinical pharmacokinetics of famotidine. *Clin Pharmacokin* 1991; 21: 178 - 94.
5. Lin JH, Chremos AN, Kanovsky SM, Schwartz S, Yeh KC, Kahn J. Effects of antacids and food on absorption of famotidine. *Br J Clin Pharmacol* 1987; 24: 551 - 53.
6. Laheij RJF, Sturkenboom MCJM, Hassing RJ, Dieleman J, Sticker BHC, Jansen JBMJ. Risk of Community – Acquired Pneumonia and Use of Gastric-Suppressive Drugs *JAMA* 2004; 292 (16): 1955-1960.
7. Product Monograph. MAXIMUM STRENGTH PEPCID® AC (famotidine tablets, MERCK Frosst Std.) Film Coated Tablets 20 mg Famotidine. McNeil Consumer Healthcare, division of Johnson and Johnson Inc. (Date of Revision: May 24, 2019) Control number 225990.

PART III: CONSUMER INFORMATION

**ACID CONTROL
Famotidine Tablets USP**

This leaflet is part III of a three-part "Product Monograph" published when ACID CONTROL was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about ACID CONTROL. Contact your doctor or pharmacist if you have any questions about the drug.

ABOUT THIS MEDICATION

What the medication is used for:

Each ACID CONTROL tablet is clinically proven to give fast and effective relief from heartburn, acid indigestion and sour or upset stomach due to excess stomach acid. ACID CONTROL when taken 10 to 15 minutes before a meal, prevents these symptoms brought on by eating or drinking food and beverages.

What it does:

It is normal for the stomach to produce acid, especially after eating food and/or drinking beverages. However, too much acid, can cause, heartburn, acid indigestion and discomfort that interfere with everyday activities. ACID CONTROL contains a medicine that actually reduces the production of excess stomach acid that causes these symptoms. ACID CONTROL is different from antacids that only neutralize existing stomach acid, but do not stop stomach acid from being produced. ACID CONTROL actually stops tough heartburn before it starts. Just one ACID CONTROL tablet provides long lasting acid control, for up to 12 hours day or night. Acid control may not directly correlate to symptom relief.

When it should not be used:

- If you are allergic to famotidine or to any component in the medication (see non-medicinal ingredients);
- If you are allergic to other acid reducers;
- With another acid reducer.

What the medicinal ingredient is:

The medicinal ingredient is famotidine.

What the nonmedicinal ingredients are:

ACID CONTROL also contains: carnauba wax, colloidal silicon dioxide, croscarmellose sodium, ferric oxide red and ferric oxide yellow, hydroxypropyl methylcellulose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, stearic acid and titanium dioxide.

What dosage forms it comes in:

ACID CONTROL (famotidine tablets 20 mg), are film coated and thus easy-to-swallow. Each beige coloured tablet contains 20 mg of famotidine and has APO over 20 embossed on one side.

WARNINGS AND PRECAUTIONS

This medicine may not be suitable for some people.

Before taking ACID CONTROL (FAMOTIDINE TABLETS 20 mg), talk to your doctor or pharmacist if:

- You are pregnant or breast-feeding;
- You have trouble swallowing, pain on swallowing, severe vomiting, passage of red/black blood in the stools, wheezing, choking, or your stomach pains continue;
- You have kidney disease, as you may need a dose adjustment;
- You have any other severe illnesses;
- You are over 40 years of age and you are experiencing new or recently changed symptoms of acid indigestion or heartburn;
- You are taking any prescription or over-the-counter medications such as nonsteroidal anti-inflammatory drugs [NSAIDs] (because NSAIDs may be causing your symptoms);
- You have a previous history of erosive esophagitis, irritable bowel syndrome or ulcer disease complications.
- You are experiencing unintended weight loss in association with your symptoms of acid indigestion or heartburn;
- You are taking a proton pump inhibitor;
- Your heartburn is frequent (> 3 times per week) and or severe;
- You have heartburn with light headedness, sweating and dizziness;
- You have chest or shoulder pain with shortness of breath, sweating, pain spreading to arms or neck, or light headedness.

HEARTBURN WARNINGS

Heartburn and acid indigestion are common; however heartburn can be a sign of a more serious medical condition, which requires medical intervention. **Stop use of this product and any other nonprescription products you are taking for heartburn and see your doctor or pharmacist if:**

- you have had heartburn for over 3 months and haven't seen a doctor about it
- your heartburn continues, worsens or returns after using heartburn medication every day for 14 days
- you often need to use heartburn medication for 14 consecutive days (for example every 6 weeks or more frequently)

- your heartburn continues after using this or any other nonprescription heartburn product

INTERACTIONS WITH THIS MEDICATION

Before you use ACID CONTROL talk to your doctor or pharmacist if:

- you are taking Itraconazole (for fungal infections).
- You are using calcium carbonate.

PROPER USE OF THIS MEDICATION

Usual dose:

Adults and children 12 years of age or older: For relief of symptoms, swallow one (1) tablet with full glass of water. For prevention of acid-related symptoms brought on by consuming food and/or beverage swallow one (1) tablet with full glass of water 10 to 15 minutes before eating. If symptoms return, you may take another tablet. Do not take more than two tablets during a 24- hour period. If symptoms get worse or persist for more than two consecutive weeks, or if new symptoms develop, stop use and consult your physician.

TIPS TO HELP AVOID ACID-RELATED SYMPTOMS

- Do not lie down or bend over soon after eating.
- If you are overweight, lose weight.
- If you smoke, stop or cut down.
- Certain foods are more likely to cause acid-related symptoms, so you should consider reducing or avoiding foods such as caffeine, chocolate, fatty foods, spicy foods and alcohol.
- Do not eat just before bedtime.
- Raise the head of your bed.
- Wear loose fitting clothing around your stomach.

Overdose:

If you think you have taken too much ACID CONTROL, contact your healthcare professional, hospital emergency department or regional poison control centre immediately, even if there are no symptoms.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

ACID CONTROL is generally well tolerated. Side effects such as headache, diarrhea, lung infections, and vomiting were reported in studies where people took either the drug or a placebo (tablet with no medication). Each group had about the same number of side effects.

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

Symptoms / effects		Talk with your healthcare professional		Stop taking drug and get immediate medical help
		Only if severe	In all cases	
Very Rare	Dizziness and sleepiness	√		
Very Rare	Stomach pain, diarrhea, dry mouth, nausea, and vomiting		√	
Very Rare	Allergic reactions such as hives, rash, itching, swelling difficulty to breath		√	

This is not a complete list of side effects. For any unexpected effects while taking ACID CONTROL, contact your doctor or pharmacist.

HOW TO STORE IT

STORAGE CONDITIONS

Store at room temperature (15°C to 30°C). Protect from light and moisture.

Keep this and all medicines out of the reach and sight of children.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html>) for information on how to report online, by mail or by fax; or

- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

If you want more information about ACID CONTROL:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Consumer Information by visiting the Health Canada website (<https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>). Find the Consumer Information on the manufacturer's website <http://www.apotex.ca/products>, or by calling 1-800-667-4708.

This leaflet was prepared by Apotex Inc., Toronto, Ontario, M9L 1T9.

Last revised: September 17, 2019